Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: Potential benefits in bone and breast

International Journal of Women's Health

Volumn 5, Issue 1, 2013, Pages 605-611

  Soe, Lin H ^a   Wurz, Gregory T ^a   Kao, Chiao Jung ^a   DeGregorio, Michael W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; Dyspareunia; Ospemifene; Osteoporosis; Vulvar and vaginal atrophy

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; LIPID; OSPEMIFENE; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

BONE; BONE TISSUE; BRAIN HEMORRHAGE; BREAST; BREAST CANCER; CARDIOEMBOLIC STROKE; DEEP VEIN THROMBOSIS; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DYSPAREUNIA; ENDOMETRIUM; HOT FLUSH; HUMAN; HYPERHIDROSIS; LIPID BLOOD LEVEL; MUSCLE SPASM; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; REVIEW; VAGINA ATROPHY; VAGINA DISCHARGE; VAGINA EPITHELIUM; VULVA DISEASE; VULVAR ATROPHY;

EID: 84884870814     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S39146     Document Type: Review

References (44)

1. Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology. 2000;141(2):809-820.
2. Anttila M, Inventor; Hormos Medical Ltd, Turku (FI), assignee. Method for enhancing the bioavailability of ospemifene. US patent 8,470,890 B2. June 25, 2013.
3. Gennari L, Merlotti D, Valleggi F, Nuti R. Ospemifene use in postmenopausal women. Expert Opin Investig Drugs. 2009;18(6):839-849.
4. McCall JL, DeGregorio MW. Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol. 2010;6(6):773-779.
5. Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric. 2009;12(4):279-285.
6. Nappi RE, Polatti F. The use of estrogen therapy in women's sexual functioning (CME). J Sex Med. 2009;6(3):603-616.
7. Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med. 2009;6(8):2133-2142.
8. Grady D, Ettinger B, Tosteson AN, Pressman A, Macer JL. Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol. 2003;102(6):1233-1239.
9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
10. Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Menopause. 2009;16(5):907-922.
11. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007;14(3 Pt 1):355-369.
12. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;4: CD001500.
13. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause. 2003;10(5): 433-439.
14. Komi J, Lankinen KS, Harkonen P, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause. 2005;12(2):202-209.
15. Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17(3):480-486.
16. Portman DJ, Bachmann GA, Simon JA. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20(6): 623-630.
17. Voipio SK, Komi J, Kangas L, Halonen K, DeGregorio MW, Erkkola RU. Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. Maturitas. 2002;43(3):207-214.
18. Simon JA, Lin VH, Radovich C, Bachmann GA. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20(4):418-427.
19. Wurz GT, Hellmann-Blumberg U, DeGregorio MW. Pharmacologic effects of ospemifene in rhesus macaques: a pilot study. Basic Clin Pharmacol Toxicol. 2008;102(6):552-558.
20. Ylikorkala O, Cacciatore B, Halonen K, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause. 2003;10(5):440-447.
21. Qu Q, Harkonen PL, Vaananen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem. 1999;73(4):500-507.
22. Komi J, Heikkinen J, Rutanen EM, Halonen K, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol. 2004;18(3):152-158.
23. Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab. 2006;24(4):314-318.
24. Morello KC, Wurz GT, DeGregorio MW. SERMs: current status and future trends. Crit Rev Oncol Hematol. 2002;43(1):63-76.
25. Wurz GT, Soe LH, Degregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas. 2013;74(3):220-225.
26. Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. 2001;77(4-5):271-279.
27. Wurz GT, Read KC, Marchisano-Karpman C, et al. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol. 2005;97(3):230-240.
28. Maglione JE, McGoldrick ET, Young LJ, et al. Polyomavirus middle T-induced mammary intraepithelial neoplasia outgrowths: single origin, divergent evolution, and multiple outcomes. Mol Cancer Ther. 2004;3(8):941-953.
29. Maglione JE, Moghanaki D, Young LJ, et al. Transgenic polyoma middle-T mice model premalignant mammary disease. Cancer Res. 2001;61(22):8298-8305.
30. Namba R, Young LJ, Maglione JE, et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res. 2005;7(6): R881-R889.
31. Burich RA, Mehta NR, Wurz GT, et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag. Tg transgenic mouse model. Menopause. 2012;19(1): 96-103.
32. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12(3):954-961.
33. Lin EY, Jones JG, Li P, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol. 2003;163(5):2113-2126.
34. Burich R, DeGregorio M. Current treatment options for vulvovaginal atrophy. Expert Rev Obstet Gynecol. 2011;6(2):141-151.
35. Rozenberg S, Vandromme J, Antoine C. Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol. 2013;9(4):216-227.
36. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684-1692.
37. Indhavivadhana S, Leerasiri P, Rattanachaiyanont M, et al. Vaginal atrophy and sexual dysfunction in current users of systemic postmenopausal hormone therapy. J Med Assoc Thai. 2010;93(6):667-675.
38. Pastore LM, Carter RA, Hulka BS, Wells E. Self-reported urogenital symptoms in postmenopausal women: Women's Health Initiative. Maturitas. 2004;49(4):292-303.
39. Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmenopausal women. Menopause. 2009;16(1):30-36.
40. Bachmann G, Bobula J, Mirkin S. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. Climacteric. 2010;13(2):132-140.
41. Mirkin S, Komm BS. Tissue-selective estrogen complexes for postmenopausal women. Maturitas. July 10, 2013. [Epub ahead of print.]
42. Bhavnani BR. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer's. J Steroid Biochem Mol Biol. 2003;85(2-5):473-482.
43. Stovall DW. Aprela, a single tablet formulation of bazedoxifene and conjugated equine estrogens (Premarin) for the potential treatment of menopausal symptoms. Curr Opin Investig Drugs. 2010;11(4): 464-471.
44. Osphena™ (ospemifene) prescribing information. Florham Park, NJ: Shionogi Inc; 2013. Available from: http://www.shionogi.com/pdf/PI/Osphena-PI.pdf. Accessed August 22, 2013.